293946003: Allergy to zuclopenthixol (finding)

• SNOMED CT Concept\Clinical finding (finding)\...
• \The disposition to develop an allergic or pseudoallergic reaction, the reaction itself or its consequences.\A propensity to developing an adverse reaction upon exposure to an agent at a dose otherwise tolerated by normal individuals. Revised nomenclature for allergy for global use:Report of the Nomenclature Review Committee of the World Allergy Organization, October 2003.\A propensity to developing a pathological immune process generally directed towards a foreign antigen, which results in tissue injury. It is most often applied to type I hypersensitivity but other hypersensitivity types especially type IV (e.g. allergic contact dermatitis) may be involved. Revised nomenclature for allergy for global use:Report of the Nomenclature Review Committee of the World Allergy Organization, October 2003.\Allergy to drug\Allergy to alpha adrenergic receptor antagonist\Allergy to zuclopenthixol (finding)
• \The disposition to develop an allergic or pseudoallergic reaction, the reaction itself or its consequences.\A propensity to developing an adverse reaction upon exposure to an agent at a dose otherwise tolerated by normal individuals. Revised nomenclature for allergy for global use:Report of the Nomenclature Review Committee of the World Allergy Organization, October 2003.\A propensity to developing a pathological immune process generally directed towards a foreign antigen, which results in tissue injury. It is most often applied to type I hypersensitivity but other hypersensitivity types especially type IV (e.g. allergic contact dermatitis) may be involved. Revised nomenclature for allergy for global use:Report of the Nomenclature Review Committee of the World Allergy Organization, October 2003.\Allergy to drug\Allergy to thioxanthene (finding)\Allergy to zuclopenthixol (finding)
• \The disposition to develop an allergic or pseudoallergic reaction, the reaction itself or its consequences.\A propensity to developing an adverse reaction upon exposure to an agent at a dose otherwise tolerated by normal individuals. Revised nomenclature for allergy for global use:Report of the Nomenclature Review Committee of the World Allergy Organization, October 2003.\A propensity to developing a pathological immune process generally directed towards a foreign antigen, which results in tissue injury. It is most often applied to type I hypersensitivity but other hypersensitivity types especially type IV (e.g. allergic contact dermatitis) may be involved. Revised nomenclature for allergy for global use:Report of the Nomenclature Review Committee of the World Allergy Organization, October 2003.\Allergy to drug\Allergy to selective serotonin re-uptake inhibitor (finding)\Allergy to zuclopenthixol (finding)
• \The disposition to develop an allergic or pseudoallergic reaction, the reaction itself or its consequences.\A propensity to developing an adverse reaction upon exposure to an agent at a dose otherwise tolerated by normal individuals. Revised nomenclature for allergy for global use:Report of the Nomenclature Review Committee of the World Allergy Organization, October 2003.\A propensity to developing a pathological immune process generally directed towards a foreign antigen, which results in tissue injury. It is most often applied to type I hypersensitivity but other hypersensitivity types especially type IV (e.g. allergic contact dermatitis) may be involved. Revised nomenclature for allergy for global use:Report of the Nomenclature Review Committee of the World Allergy Organization, October 2003.\Allergy to histamine H1 receptor antagonist (finding)\Allergy to zuclopenthixol (finding)
• \The disposition to develop an allergic or pseudoallergic reaction, the reaction itself or its consequences.\The disposition to develop an allergic reaction, the allergic reaction itself or its consequences.\A propensity to developing a pathological immune process generally directed towards a foreign antigen, which results in tissue injury. It is most often applied to type I hypersensitivity but other hypersensitivity types especially type IV (e.g. allergic contact dermatitis) may be involved. Revised nomenclature for allergy for global use:Report of the Nomenclature Review Committee of the World Allergy Organization, October 2003.\Allergy to drug\Allergy to alpha adrenergic receptor antagonist\Allergy to zuclopenthixol (finding)
• \The disposition to develop an allergic or pseudoallergic reaction, the reaction itself or its consequences.\The disposition to develop an allergic reaction, the allergic reaction itself or its consequences.\A propensity to developing a pathological immune process generally directed towards a foreign antigen, which results in tissue injury. It is most often applied to type I hypersensitivity but other hypersensitivity types especially type IV (e.g. allergic contact dermatitis) may be involved. Revised nomenclature for allergy for global use:Report of the Nomenclature Review Committee of the World Allergy Organization, October 2003.\Allergy to drug\Allergy to thioxanthene (finding)\Allergy to zuclopenthixol (finding)
• \The disposition to develop an allergic or pseudoallergic reaction, the reaction itself or its consequences.\The disposition to develop an allergic reaction, the allergic reaction itself or its consequences.\A propensity to developing a pathological immune process generally directed towards a foreign antigen, which results in tissue injury. It is most often applied to type I hypersensitivity but other hypersensitivity types especially type IV (e.g. allergic contact dermatitis) may be involved. Revised nomenclature for allergy for global use:Report of the Nomenclature Review Committee of the World Allergy Organization, October 2003.\Allergy to drug\Allergy to selective serotonin re-uptake inhibitor (finding)\Allergy to zuclopenthixol (finding)
• \The disposition to develop an allergic or pseudoallergic reaction, the reaction itself or its consequences.\The disposition to develop an allergic reaction, the allergic reaction itself or its consequences.\A propensity to developing a pathological immune process generally directed towards a foreign antigen, which results in tissue injury. It is most often applied to type I hypersensitivity but other hypersensitivity types especially type IV (e.g. allergic contact dermatitis) may be involved. Revised nomenclature for allergy for global use:Report of the Nomenclature Review Committee of the World Allergy Organization, October 2003.\Allergy to histamine H1 receptor antagonist (finding)\Allergy to zuclopenthixol (finding)
• \Propensity to adverse reaction\A propensity to developing an adverse reaction upon exposure to an agent at a dose otherwise tolerated by normal individuals. Revised nomenclature for allergy for global use:Report of the Nomenclature Review Committee of the World Allergy Organization, October 2003.\A propensity to developing a pathological immune process generally directed towards a foreign antigen, which results in tissue injury. It is most often applied to type I hypersensitivity but other hypersensitivity types especially type IV (e.g. allergic contact dermatitis) may be involved. Revised nomenclature for allergy for global use:Report of the Nomenclature Review Committee of the World Allergy Organization, October 2003.\Allergy to drug\Allergy to alpha adrenergic receptor antagonist\Allergy to zuclopenthixol (finding)
• \Propensity to adverse reaction\A propensity to developing an adverse reaction upon exposure to an agent at a dose otherwise tolerated by normal individuals. Revised nomenclature for allergy for global use:Report of the Nomenclature Review Committee of the World Allergy Organization, October 2003.\A propensity to developing a pathological immune process generally directed towards a foreign antigen, which results in tissue injury. It is most often applied to type I hypersensitivity but other hypersensitivity types especially type IV (e.g. allergic contact dermatitis) may be involved. Revised nomenclature for allergy for global use:Report of the Nomenclature Review Committee of the World Allergy Organization, October 2003.\Allergy to drug\Allergy to thioxanthene (finding)\Allergy to zuclopenthixol (finding)
• \Propensity to adverse reaction\A propensity to developing an adverse reaction upon exposure to an agent at a dose otherwise tolerated by normal individuals. Revised nomenclature for allergy for global use:Report of the Nomenclature Review Committee of the World Allergy Organization, October 2003.\A propensity to developing a pathological immune process generally directed towards a foreign antigen, which results in tissue injury. It is most often applied to type I hypersensitivity but other hypersensitivity types especially type IV (e.g. allergic contact dermatitis) may be involved. Revised nomenclature for allergy for global use:Report of the Nomenclature Review Committee of the World Allergy Organization, October 2003.\Allergy to drug\Allergy to selective serotonin re-uptake inhibitor (finding)\Allergy to zuclopenthixol (finding)
• \Propensity to adverse reaction\A propensity to developing an adverse reaction upon exposure to an agent at a dose otherwise tolerated by normal individuals. Revised nomenclature for allergy for global use:Report of the Nomenclature Review Committee of the World Allergy Organization, October 2003.\A propensity to developing a pathological immune process generally directed towards a foreign antigen, which results in tissue injury. It is most often applied to type I hypersensitivity but other hypersensitivity types especially type IV (e.g. allergic contact dermatitis) may be involved. Revised nomenclature for allergy for global use:Report of the Nomenclature Review Committee of the World Allergy Organization, October 2003.\Allergy to histamine H1 receptor antagonist (finding)\Allergy to zuclopenthixol (finding)
• \Propensity to adverse reaction\Propensity to adverse reactions to drug\Allergy to drug\Allergy to alpha adrenergic receptor antagonist\Allergy to zuclopenthixol (finding)
• \Propensity to adverse reaction\Propensity to adverse reactions to drug\Allergy to drug\Allergy to thioxanthene (finding)\Allergy to zuclopenthixol (finding)
• \Propensity to adverse reaction\Propensity to adverse reactions to drug\Allergy to drug\Allergy to selective serotonin re-uptake inhibitor (finding)\Allergy to zuclopenthixol (finding)

Status: current, Sufficiently defined by necessary conditions definition status (core metadata concept). Date: 31-Jan 2006. Module: SNOMED CT core

Descriptions:

Id	Description	Lang	Type	Status	Case?	Module
434197017	Zuclopenthixol allergy	en	Synonym (core metadata concept)	Active	Entire term case insensitive (core metadata concept)	SNOMED CT core
3748540019	Allergy to zuclopenthixol (finding)	en	Fully specified name	Active	Entire term case insensitive (core metadata concept)	SNOMED CT core
3749820010	Allergy to zuclopenthixol	en	Synonym (core metadata concept)	Active	Entire term case insensitive (core metadata concept)	SNOMED CT core
367681000195116	allergia allo zuclopentixolo	it	Synonym (core metadata concept)	Active	Entire term case insensitive (core metadata concept)	SNOMED CT Switzerland NRC maintained Module
747201000172112	allergie au zuclopenthixol	fr	Synonym (core metadata concept)	Active	Entire term case insensitive (core metadata concept)	SNOMED CT Switzerland NRC maintained Module

Expanded Value Set

This concept is not in any reference sets

Back to Start